Sender Company & Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12M Buy
13,000
+4,378
+51% +$4.44M 7.27% 5
2025
Q4
$9.27M Sell
8,622
-793
-8% -$758K 4.32% 3
2025
Q3
$7.18M Buy
9,415
+2,053
+28% +$1.53M 0.79% 22
2025
Q2
$5.74M Buy
7,362
+5,972
+430% +$4.64M 1.62% 12
2025
Q1
$1.15M Buy
+1,390
New +$1.16M 0.6% 42
2024
Q1
Sell
-2,139
Closed -$1.25M 47
2023
Q4
$1.25M Buy
+2,139
New +$1.25M 2.39% 15
2022
Q4
Sell
-1,812
Closed -$586K 62
2022
Q3
$586K Buy
+1,812
New +$574K 1.44% 16

Other funds holding LLY

Sender Company & Partners's LLY Position: Q1 2026 in Review

Sender Company & Partners increased its Eli Lilly (LLY) stake by 51% in Q1 2026, buying an estimated $4.44M and bringing the position to 13,000 shares worth $12M. The position accounts for 7.27% of the portfolio, ranked #5.

Sender Company & Partners first reported a position in LLY in Q3 2022 and has held it in 7 quarters since. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Sender Company & Partners held 13,000 shares of Eli Lilly worth $12M as of Q1 2026.
  • Sender Company & Partners bought 4,378 Eli Lilly shares in Q1 2026, an estimated $4.44M.
  • Eli Lilly made up 7.27% of Sender Company & Partners's portfolio in Q1 2026, its #5 holding.
  • Sender Company & Partners first reported a position in Eli Lilly in Q3 2022 and has held it in 7 quarters since.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Sender Company & Partners's 13F filing for Q1 2026, filed 15 May 2026.